N/A N=39 Glucocorticoids and Bone in Graves' Ophthalmopathy
Graves Ophthalmopathy
Primary: Percent Change Lumbar Spine Bone Mineral Density — 1.37 Percentage change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=100 Pilot Guaranteed Income Study, Philadelphia, April 2023
Cardiovascular Diseases
Primary: Change in Food Security Category — 27; 19; 16; 23 Participants
Phase 4 N=372 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
Human Papillomavirus Infection
Primary: HPV Incidence Rates, Expressed as Incident Infections/1000 Infection-months at Risk. These Were Calculated Separately for Females and Males Across the Four Vaccine…
Phase 2 N=32 Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
Recurrent Colorectal Carcinoma · Progressive Colorectal Carcinoma
Primary: Safety and Maximum Tolerated Dosage of Imprime PGG When Used in Combination With Cetuximab With or Without Irinotecan Therapy — 3; 7; 4; 9 participants
N/A N=23 Resistance Exercise and Low-Intensity Physical Activity Breaks in Sedentary Time to Improve Muscle and Cardiometabolic Health
Aging · Sarcopenia · Disability Physical
Primary: Skeletal Muscle Strength — 93.9; 50.0; 78.6 Change in Lbs
Phase 4 N=13 Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes
Cystic Fibrosis-related Diabetes
Primary: Time in Target — 67; 68 percentage of time in range — p=<0.01
Phase 3 N=213 Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
Glabellar Frown Lines
Primary: Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the…
Phase 3 N=6 A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic Thrombocytopenic Purpura (TTP)
Primary: Number of Participants With Acute Thrombotic Thrombocytopenic Purpura (TTP) Events During Prophylactic Treatment — 0; 0; 1 Participants
N/A N=186 Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics)
Opioid-use Disorder
Primary: CM Exposure (Implementation Outcome) — 18; 31 Participants — p=0.097
N/A N=60 Use Of An In-Home Non-Stress Test Device For Remote Fetal Monitoring
High Risk Pregnancy
Primary: Number of Interpretable Results (Participants Who Used the NST Device Correctly) — 107; 1 Remote NST's Completed — p=.1
N/A N=33 Exposure-Based Treatment for Undifferentiated Somatic Symptom Disorder
Somatic Symptom Disorder
Primary: Feasibility 1: Distribution of Physical Symptoms — 11.8 score on a scale
Phase 4 N=90 Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN
Hypertension · Genetics Hypertension
Primary: Systolic /Diastolic Supine Morning Liberal Salt Automated Blood Pressure — 144.2; 148.5; 86.0; 91.4 mm hg — p=0.823
N/A N=30 Women's Interventions for Sexual Health: WISH
Sexual Dysfunction, Physiological · Body Image · Libido; Loss, Aversion
Primary: Screen Failure Rate (a Measure of Feasibility) — 36 Participants
N/A N=101 Peers and Technology for Adherence, Access, Accountability, and Analytics
Hypertension · Medication Adherence
Primary: Absolute Mean Change in Systolic Blood Pressure (SBP) — 11.5 millimeters of mercury (mmHg)
N/A N=115 Efficacy of the Quell Wearable Device for Chronic Overlapping Pain Conditions
Chronic Pain · Adults 21 and Older · Multiple Chronic Overlapping Pain Conditions
Primary: The Brief Pain Inventory Interference Scale (BPI) — 5.7; 5.7 score on a scale